A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs have become the company’s key top-line drivers. In the ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point for the accessibility of weight loss drugs. Since then, Zepbound, the ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.